Sareum Holdings PLC

Sareum Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)131.22
  • Today's Change-3.78 / -2.80%
  • Shares traded61.91k
  • 1 Year change-40.35%
  • Beta-0.4685
Data delayed at least 20 minutes, as of Jun 06 2023 11:42 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-2.76m
  • Incorporated2004
  • Employees5.00
  • Location
    Sareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
  • Phone+44 122 349 7700
  • Fax+44 122 349 7701
  • Websitehttps://sareum.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
CRUSHMETRIC Group Ltd911.68k-196.15k48.03m6.00------52.68-0.0022-0.00220.0104-0.04741.065.145.24---64.23-118.75----46.1238.24-60.68-156.870.0909-10.54-----75.86-14.62-156.85------
Shield Therapeutics PLC4.47m-40.44m48.13m23.00--3.77--10.77-0.1661-0.16610.01880.01790.13441.601.08---121.66-38.57-154.17-43.0944.7180.67-905.40-253.150.8118--0.5291--194.0847.63-105.53---11.08--
Venture Life Group PLC43.98m520.00k48.70m153.00110.000.64378.251.110.00350.00350.32970.59810.38422.503.07287,451.000.45431.750.51512.0140.1740.301.184.411.342.190.26190.0034.2422.33-78.35--37.59--
Spectral MD Holdings Ltd20.40m-2.34m61.34m71.00--6.32--3.01-0.0173-0.01730.15060.07121.36--13.61287,283.70-15.63---22.32--42.72---11.48-----12.730.0788--66.47--44.50------
4Basebio PLC268.00k-5.15m69.61m----9.77--259.72-0.4181-0.41810.02180.578----------------89.18---1,921.64--3.80-65.620.32---20.71---59.20------
Eco Animal Health Group Plc78.58m779.00k70.77m221.0091.670.845122.270.90060.01140.01141.161.240.66951.522.93355,565.601.097.781.5310.0642.5346.981.6310.422.14--0.018353.51-22.176.00-109.35---18.83--
Arecor Therapeutics PLC2.40m-9.26m76.55m51.00--4.39--31.85-0.3198-0.31980.0830.57010.1126--0.837447,117.65-43.39---50.48-------385.35--4.38--0.0162--107.51---50.11------
Creo Medical Group PLC27.17m-26.94m85.09m284.00--0.9234--3.13-0.1434-0.14340.14460.26260.30881.584.6995,665.49-30.62---38.83--48.30---99.14--1.39-139.170.1913--7.98---9.52------
Sareum Holdings Plc0.00-2.76m91.89m5.00--31.85-----0.0406-0.04060.000.04240.00----0.00-59.88-64.34-64.48-71.09-------16,059.92----0.00-------44.76---28.45--
Redx Pharma PLC12.65m-29.01m93.78m71.00--6.28--7.41-0.0883-0.08830.0390.04460.3056--47.28---70.08-44.98-148.14-70.15-----229.35-164.47----0.5574--86.25-9.3116.55--11.21--
e-Therapeutics plc475.00k-8.27m99.20m38.00--3.00--208.84-0.0154-0.01540.00090.05680.0148--1.9212,500.00-25.79-33.25-27.10-35.11100.00100.00-1,741.90-1,490.90----0.0089---0.4193---2.53--24.22--
Celadon Pharmaceuticals PLC-100.00bn-100.00bn100.21m----9.01----------0.1804------------------------6.96--0.301--------------
Open Orphan PLC48.48m-776.00k104.19m235.00--5.0948.372.15-0.0012-0.00120.07230.03011.04--4.44206,285.10-1.66-15.59-3.59-31.13-----1.60-17.761.40--0.0718--31.5026.01-948.65--24.47--
Animalcare Group Plc71.62m1.97m109.07m211.0056.091.3811.171.520.03240.03241.181.310.62752.606.92--1.720.08772.050.102656.7752.292.740.15620.91217.670.12652,045.05-3.25--2,651.95------
Futura Medical PLC0.00-5.85m121.59m12.00--25.76-----0.0203-0.02030.000.01640.00----0.00-63.98-75.22-80.95-106.12-------88,144.94----0.00-------17.93--67.85--
Scancell Holdings Plc0.00-8.44m126.85m40.00--8.19-----0.0104-0.01040.000.01890.00----0.00-20.30-31.06-21.45-33.18-----------19.720.3805------86.66--83.42--
Data as of Jun 06 2023. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

13.01%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Asset Management Ltd.as of 02 Apr 20234.35m6.38%
HSBC Global Asset Management (UK) Ltd.as of 02 Apr 20232.92m4.28%
Jarvis Investment Management Ltd.as of 02 Apr 2023573.00k0.84%
IG Markets Ltd.as of 02 Apr 2023451.00k0.66%
Rowan Dartington & Co. Ltd. (Broker)as of 02 Apr 2023170.00k0.25%
J. M. Finn & Co. Ltd.as of 02 Apr 202394.00k0.14%
Evelyn Partners Investment Management Services Ltd.as of 02 Apr 202387.00k0.13%
Walker Crips Investment Management Ltd.as of 02 Apr 202376.00k0.11%
iDealing.com Ltd.as of 02 Apr 202375.00k0.11%
Eurizon Capital SGR SpAas of 02 Apr 202366.00k0.10%
More ▼
Data from 31 Mar 2022 - 31 May 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.